BAY86-5046 (Betaseron), Non Interventional Studies

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to investigate adherence to therapy among patients treated with Betaferon who are using the BETACONNECT autoinjector.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Interferon beta-1b; Interferon-beta; Interferons

Criteria

Inclusion Criteria:

• Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome.

• Patients must be on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician.

• Patient and attending physicians must have agreed on the usage of the BETACONNECT auto-injector device

• Written informed consent must be obtained.

Exclusion Criteria:

• Patients receiving any other disease modifying drug.

• Contraindications of Betaferon described in the Summary of Product Characteristics.